Quantum BioPharma Rejects Law Firms' Allegations as Unsubstantiated
Quantum BioPharma Ltd. has formally refuted securities law violation claims from two law firms, calling them vague and unsubstantiated attempts to mislead investors and damage the company's reputation.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has issued a formal response rejecting what it described as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company stated that the announcements lack factual detail or context and appear intended to mislead investors and provoke unwarranted concern.
The biopharmaceutical company said it is reviewing the conduct of both firms and their principals and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation. This development comes as Quantum BioPharma continues its work in developing treatments for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. This patented new chemical entity has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company's latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
Quantum BioPharma also maintains strategic business interests through its ownership stake in Unbuzzd Wellness Inc., where it retains 20.11% ownership as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The company's response to the law firm allegations highlights the importance of transparent communication in the biopharmaceutical sector, where investor confidence can significantly impact research and development efforts. Quantum BioPharma's full press release addressing these matters can be viewed at https://ibn.fm/TsBbx.
This situation underscores the challenges faced by emerging biotech companies in navigating legal and regulatory landscapes while maintaining focus on their core mission of developing innovative treatments for serious medical conditions. The company's portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., represents additional business interests that could be affected by such legal challenges.